Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:LLY
- CUSIP: 53245710
- Web: www.lilly.com
Capitalization:- Market Cap: $92.38399 billion
- Outstanding Shares: 1,055,000,000
Average Prices:- 50 Day Moving Avg: $80.84
- 200 Day Moving Avg: $82.02
- 52 Week Range: $64.18 - $86.72
P/E:- Trailing P/E Ratio: 36.62
- Foreward P/E Ratio: 18.36
- P/E Growth: 1.77
Sales & Book Value:- Annual Revenue: $22 billion
- Price / Sales: 4.02
- Book Value: $13.37 per share
- Price / Book: 6.28
Dividend:- Annual Dividend: $2.08
- Dividend Yield: 2.5%
Profitability:- EBIDTA: $5.99 billion
- Net Margins: 11.12%
- Return on Equity: 28.71%
- Return on Assets: 10.74%
Debt:- Debt-to-Equity Ratio: 0.70%
- Current Ratio: 1.39%
- Quick Ratio: 1.01%
Misc:- Average Volume: 3.48 million shs.
- Beta: 0.34
- Short Ratio: 2.62
Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)
What is Eli Lilly and Company's stock symbol?
Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?
Eli Lilly and Company announced a quarterly dividend on Monday, June 19th. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend is Friday, August 11th. View Eli Lilly and Company's Dividend History.
How were Eli Lilly and Company's earnings last quarter?
Eli Lilly and Company (NYSE:LLY) issued its earnings results on Tuesday, July, 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and Company had a net margin of 11.12% and a return on equity of 28.71%. The company's revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.86 earnings per share. View Eli Lilly and Company's Earnings History.
When will Eli Lilly and Company make its next earnings announcement?
What guidance has Eli Lilly and Company issued on next quarter's earnings?
Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.
Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?
18 brokers have issued 12-month price objectives for Eli Lilly and Company's stock. Their predictions range from $71.00 to $105.00. On average, they anticipate Eli Lilly and Company's stock price to reach $89.18 in the next twelve months. View Analyst Ratings for Eli Lilly and Company.
What are analysts saying about Eli Lilly and Company stock?
Here are some recent quotes from research analysts about Eli Lilly and Company stock:
- 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
- 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
- 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)
Who are some of Eli Lilly and Company's key competitors?
Some companies that are related to Eli Lilly and Company include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO) and Akorn (AKRX).
Who are Eli Lilly and Company's key executives?
Eli Lilly and Company's management team includes the folowing people:
- David A. Ricks, Chairman of the Board, President, Chief Executive Officer
- Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
- Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
- Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
- Michael J. Harrington, Senior Vice President, General Counsel
- Stephen F. Fry, Senior Vice President - Human Resources and Diversity
- Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
- Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
- Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
- Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications
Who owns Eli Lilly and Company stock?
Eli Lilly and Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Lilly Endowment Inc. (11.76%), Vanguard Group Inc. (6.65%), BlackRock Inc. (6.03%), State Street Corp (3.98%), Franklin Resources Inc. (2.66%) and State Farm Mutual Automobile Insurance Co. (1.89%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.
Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?
Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Winslow Capital Management LLC, Franklin Resources Inc., Bank of New York Mellon Corp, FMR LLC, American Century Companies Inc., UBS Asset Management Americas Inc. and Capital Guardian Trust Co.. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.
Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?
Eli Lilly and Company's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dodge & Cox, Renaissance Technologies LLC, Harbour Capital Advisors LLC, Vanguard Group Inc., AJO LP, Westfield Capital Management Co. LP and BlackRock Inc.. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.
How do I buy Eli Lilly and Company stock?
Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly and Company's stock price today?
One share of Eli Lilly and Company stock can currently be purchased for approximately $83.91.
MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Hold Ratings, 11 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.56) |
| Consensus Price Target: | $89.18 (6.28% upside) |
Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/15/2017 | Morgan Stanley | Reiterated Rating | Hold | $86.00 | Low |  |
| 9/11/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $89.00 -> $89.00 | Low | |
| 9/8/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $103.00 -> $105.00 | Low | |
| 9/6/2017 | BMO Capital Markets | Reiterated Rating | Underperform | $73.00 -> $71.00 | Low | |
| 8/31/2017 | Leerink Swann | Reiterated Rating | Hold | | Low | |
| 8/4/2017 | Berenberg Bank | Reiterated Rating | Buy | $98.00 | Low | |
| 7/26/2017 | Oppenheimer Holdings, Inc. | Downgrade | Outperform -> Market Perform | $90.00 -> $90.00 | Low | |
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $90.00 -> $91.00 | Low | |
| 7/4/2017 | Citigroup Inc. | Reiterated Rating | Buy | $100.00 | Low | |
| 7/4/2017 | Barclays PLC | Boost Price Target | Overweight | $85.00 -> $90.00 | Low | |
| 5/21/2017 | Sanford C. Bernstein | Reiterated Rating | Outperform | $88.00 | Medium | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Conviction-Buy -> Buy | $92.00 | High | |
| 4/27/2017 | Argus | Downgrade | Buy -> Hold | $64.18 -> $81.00 | Low | |
| 4/19/2017 | Credit Suisse Group | Reiterated Rating | Outperform | $87.00 | Low | |
| 4/17/2017 | Cowen and Company | Boost Price Target | Outperform | $85.00 -> $95.00 | Medium | |
| 11/26/2016 | J P Morgan Chase & Co | Reiterated Rating | Overweight | | N/A | |
| 11/25/2016 | Atlantic Securities | Downgrade | Overweight -> Neutral | | N/A | |
| 10/27/2016 | Societe Generale | Reiterated Rating | Hold | $78.00 | N/A | |
| 6/15/2016 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | N/A | |
| 12/22/2015 | Bank of America Corporation | Reiterated Rating | Buy | $104.00 -> $108.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Eli Lilly and Company (NYSE:LLY)Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | $1.03 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $1.05 | $1.11 | $5.60 billion | $5.82 billion | View | N/A | |
| 4/25/2017 | Q1 17 | $0.96 | $0.98 | $5.22 billion | $5.23 billion | View | N/A | |
| 1/31/2017 | Q416 | $0.98 | $0.95 | $5.54 billion | $5.76 billion | View | N/A | |
| 10/25/2016 | Q316 | $0.96 | $0.88 | $4.23 billion | $5.19 billion | View | Listen | |
| 7/26/2016 | Q216 | $0.86 | $0.86 | $5.14 billion | $5.40 billion | View | Listen | |
| 4/26/2016 | Q116 | $0.85 | $0.83 | $4.82 billion | $4.87 billion | View | Listen | |
| 1/28/2016 | Q415 | $0.78 | $0.78 | $5.33 billion | $5.38 billion | View | Listen | |
| 10/22/2015 | Q315 | $0.76 | $0.89 | $4.99 billion | $4.96 billion | View | Listen | |
| 7/23/2015 | Q215 | $0.74 | $0.90 | $4.89 billion | $4.98 billion | View | Listen | |
| 4/23/2015 | Q115 | $0.76 | $0.87 | $4.62 billion | $4.64 billion | View | N/A | |
| 1/30/2015 | Q414 | $0.74 | $0.75 | $5.21 billion | $5.12 billion | View | N/A | |
| 10/23/2014 | Q314 | $0.66 | $0.66 | $4.83 billion | $4.88 billion | View | Listen | |
| 7/24/2014 | Q214 | $0.66 | $0.68 | $4.88 billion | $4.94 billion | View | N/A | |
| 4/24/2014 | Q114 | $0.70 | $0.70 | $4.78 billion | $4.68 billion | View | N/A | |
| 1/30/2014 | Q413 | $0.72 | $0.74 | $5.46 billion | $5.81 billion | View | Listen | |
| 10/23/2013 | Q313 | $1.04 | $1.11 | $5.76 billion | $5.77 billion | View | N/A | |
| 7/24/2013 | Q2 2013 | $1.01 | $1.16 | $5.82 billion | $5.93 billion | View | N/A | |
| 4/24/2013 | Q1 2013 | $1.05 | $1.14 | $5.66 billion | $5.60 billion | View | N/A | |
| 1/29/2013 | Q4 2012 | $0.82 | $0.85 | $5.78 billion | $5.96 billion | View | N/A | |
| 10/24/2012 | | $0.82 | $0.79 | | | View | N/A | |
| 7/25/2012 | | $0.76 | $0.83 | | | View | N/A | |
| 4/25/2012 | | $0.80 | $0.92 | | | View | N/A | |
| 1/31/2012 | | $0.80 | $0.87 | | | View | N/A | |
| 10/20/2011 | | $1.12 | $1.13 | | | View | N/A | |
| 7/21/2011 | | $1.18 | $1.18 | | | View | N/A | |
| 4/18/2011 | | $1.16 | $1.24 | | | View | N/A | |
| 1/27/2011 | | $1.10 | $1.11 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Eli Lilly and Company (NYSE:LLY)2017 EPS Consensus Estimate: $4.10
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.98 | $0.98 | $0.98 |
| Q2 2017 | 2 | $1.04 | $1.06 | $1.05 |
| Q3 2017 | 2 | $1.03 | $1.06 | $1.05 |
| Q4 2017 | 2 | $1.01 | $1.04 | $1.03 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Eli Lilly and Company (NYSE:LLY)| Most Recent Dividend: | 9/8/2017 |
| Annual Dividend: | $2.08 |
| Dividend Yield: | 2.48% |
| Dividend Growth: | 1.30% (3 Year Average) |
| Payout Ratio: | 90.04% (Trailing 12 Months of Earnings)
50.12% (Based on This Year's Estimates)
45.51% (Based on Next Year's Estimates)
|
| Track Record: | 2 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 6/19/2017 | quarterly | $0.52 | 2.51% | 8/11/2017 | 8/15/2017 | 9/8/2017 |
| 5/1/2017 | quarterly | $0.52 | 2.55% | 5/11/2017 | 5/15/2017 | 6/9/2017 |
| 12/13/2016 | quarterly | $0.52 | 3.03% | 2/13/2017 | 2/15/2017 | 3/10/2017 |
| 10/17/2016 | quarterly | $0.51 | 2.59% | 11/10/2016 | 11/15/2016 | 12/9/2016 |
| 6/20/2016 | quarterly | $0.51 | 2.81% | 8/11/2016 | 8/15/2016 | 9/9/2016 |
| 5/2/2016 | quarterly | $0.51 | 2.68% | 5/11/2016 | 5/13/2016 | 6/10/2016 |
| 12/8/2015 | quarterly | $0.51 | 2.43% | 2/10/2016 | 2/12/2016 | 3/10/2016 |
| 10/19/2015 | quarterly | $0.50 | 2.57% | 11/10/2015 | 11/13/2015 | 12/10/2015 |
| 6/15/2015 | quarterly | $0.50 | 2.42% | 8/12/2015 | 8/14/2015 | 9/10/2015 |
| 5/4/2015 | quarterly | $0.50 | 2.78% | 5/14/2015 | 5/18/2015 | 6/10/2015 |
| 12/15/2014 | quarterly | $0.50 | 2.89% | 2/11/2015 | 2/13/2015 | 3/10/2015 |
| 10/20/2014 | quarterly | $0.49 | 3.03% | 11/12/2014 | 11/14/2014 | 12/10/2014 |
| 6/16/2014 | quarterly | $0.49 | 3.31% | 8/13/2014 | 8/15/2014 | 9/10/2014 |
| 5/5/2014 | quarterly | $0.49 | 3.35% | 5/13/2014 | 5/15/2014 | 6/10/2014 |
| 12/16/2013 | quarterly | $0.49 | 3.98% | 2/12/2014 | 2/14/2014 | 3/10/2014 |
| 10/21/2013 | quarterly | $0.49 | 3.91% | 11/13/2013 | 11/15/2013 | 12/10/2013 |
| 6/18/2013 | quarterly | $0.49 | 3.82% | 8/13/2013 | 8/15/2013 | 9/10/2013 |
| 5/6/2013 | quarterly | $0.49 | 3.62% | 5/14/2013 | 5/16/2013 | 6/10/2013 |
| 12/17/2012 | quarterly | $0.49 | 3.96% | 2/13/2013 | 2/15/2013 | 3/8/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.72%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/15/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $82.53 | $15,680,700.00 | |
| 8/31/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $81.06 | $14,590,800.00 | |
| 7/31/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 220,000 | $83.09 | $18,279,800.00 | |
| 6/22/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $84.43 | $17,730,300.00 | |
| 6/20/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 215,000 | $83.05 | $17,855,750.00 | |
| 6/12/2017 | Melissa S Barnes | Insider | Sell | 1,900 | $80.78 | $153,482.00 | |
| 6/9/2017 | Michael J Harrington | VP | Sell | 22,833 | $79.97 | $1,825,955.01 | |
| 5/4/2017 | Enrique A Conterno | SVP | Sell | 25,000 | $82.76 | $2,069,000.00 | |
| 3/30/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $84.67 | $17,780,700.00 | |
| 2/17/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 230,000 | $80.27 | $18,462,100.00 | |
| 2/6/2017 | Alfonso G Zulueta | SVP | Sell | 15,000 | $77.66 | $1,164,900.00 | |
| 2/3/2017 | Derica W Rice | EVP | Sell | 11,162 | $77.14 | $861,036.68 | |
| 2/2/2017 | Donald A Zakrowski | Insider | Sell | 2,000 | $77.52 | $155,040.00 | |
| 2/1/2017 | Lilly Endowment Inc | Major Shareholder | Sell | 220,000 | $77.35 | $17,017,000.00 | |
| 12/16/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $72.59 | $14,518,000.00 | |
| 12/16/2016 | Melissa S Barnes | Insider | Sell | 2,093 | $82.23 | $172,107.39 | |
| 12/16/2016 | R David Hoover | Director | Buy | 500 | $71.85 | $35,925.00 | |
| 12/16/2016 | Susan Mahony | SVP | Sell | 20,242 | $72.65 | $1,470,581.30 | |
| 10/5/2016 | Maria A Crowe | Insider | Sell | 2,248 | $81.37 | $182,919.76 | |
| 8/15/2016 | Jackson P Tai | Director | Buy | 5,773 | $80.43 | $464,322.39 | |
| 8/12/2016 | Jackson P Tai | Director | Buy | 2,560 | $80.42 | $205,875.20 | |
| 7/29/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 205,000 | $82.94 | $17,002,700.00 | |
| 7/28/2016 | Donald A Zakrowski | Insider | Sell | 1,213 | $83.16 | $100,873.08 | |
| 7/28/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 240,000 | $82.87 | $19,888,800.00 | |
| 7/12/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $79.54 | $16,703,400.00 | |
| 7/7/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 225,000 | $79.14 | $17,806,500.00 | |
| 6/30/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 215,000 | $78.46 | $16,868,900.00 | |
| 6/29/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 220,000 | $77.86 | $17,129,200.00 | |
| 6/10/2016 | Melissa S Barnes | SVP | Sell | 992 | $73.77 | $73,179.84 | |
| 5/31/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $75.12 | $15,024,000.00 | |
| 5/12/2016 | Jackson P Tai | Director | Buy | 1,080 | $75.75 | $81,810.00 | |
| 5/12/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $75.86 | $14,413,400.00 | |
| 5/2/2016 | Donald A Zakrowski | CAO | Sell | 1,600 | $75.86 | $121,376.00 | |
| 4/29/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $75.44 | $13,579,200.00 | |
| 4/27/2016 | Alfonso G Zulueta | SVP | Sell | 12,000 | $76.27 | $915,240.00 | |
| 4/8/2016 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $74.29 | $14,858,000.00 | |
| 2/5/2016 | Stephen F Fry | SVP | Sell | 15,230 | $78.87 | $1,201,190.10 | |
| 2/3/2016 | David A. Ricks | SVP | Sell | 5,733 | $77.66 | $445,224.78 | |
| 2/3/2016 | Derica W. Rice | CFO | Sell | 10,483 | $77.78 | $815,367.74 | |
| 2/1/2016 | Jackson P Tai | Director | Buy | 3,170 | $78.62 | $249,225.40 | |
| 1/29/2016 | Alfonso G Zulueta | SVP | Sell | 5,000 | $78.75 | $393,750.00 | |
| 12/21/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 205,000 | $86.00 | $17,630,000.00 | |
| 12/15/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 215,000 | $85.60 | $18,404,000.00 | |
| 12/9/2015 | Enrique A Conterno | VP | Sell | 25,000 | $83.88 | $2,097,000.00 | |
| 12/2/2015 | Lilly Endowment Inc | major shareholder | Sell | 210,000 | $85.09 | $17,868,900.00 | |
| 11/20/2015 | Lilly Endowment Inc | major shareholder | Sell | 205,000 | $84.54 | $17,330,700.00 | |
| 10/29/2015 | Lilly Endowment Inc | major shareholder | Sell | 200,000 | $82.28 | $16,456,000.00 | |
| 10/9/2015 | Lilly Endowment Inc | major shareholder | Sell | 215,000 | $85.86 | $18,459,900.00 | |
| 10/5/2015 | Lilly Endowment Inc | major shareholder | Sell | 260,000 | $86.46 | $22,479,600.00 | |
| 9/18/2015 | Lilly Endowment Inc | major shareholder | Sell | 250,000 | $89.04 | $22,260,000.00 | |
| 6/10/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $82.39 | $17,301,900.00 | |
| 6/4/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $77.90 | $15,580,000.00 | |
| 5/29/2015 | Jeffrey N Simmons | SVP | Sell | 20,000 | $78.08 | $1,561,600.00 | |
| 5/20/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $73.43 | $13,951,700.00 | |
| 5/15/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $72.83 | $14,566,000.00 | |
| 5/8/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 195,000 | $73.28 | $14,289,600.00 | |
| 5/1/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $73.09 | $14,618,000.00 | |
| 3/30/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $73.94 | $13,309,200.00 | |
| 3/23/2015 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $76.97 | $14,624,300.00 | |
| 3/9/2015 | Stephen F Fry | SVP | Sell | 4,000 | $69.27 | $277,080.00 | |
| 2/4/2015 | David A Ricks | SVP | Sell | 3,147 | $69.99 | $220,258.53 | |
| 2/4/2015 | Derica W Rice | CFO | Sell | 5,316 | $70.00 | $372,120.00 | |
| 2/4/2015 | Jan M Lundberg | EVP | Sell | 11,085 | $70.08 | $776,836.80 | |
| 2/3/2015 | Jan M Lundberg | EVP | Sell | 121,711 | $70.78 | $8,614,704.58 | |
| 2/2/2015 | David A Ricks | SVP | Sell | 4,769 | $71.51 | $341,031.19 | |
| 2/2/2015 | Derica W Rice | CFO | Sell | 10,068 | $71.84 | $723,285.12 | |
| 12/4/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $71.92 | $13,664,800.00 | |
| 12/2/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $70.14 | $12,625,200.00 | |
| 11/13/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $67.73 | $13,546,000.00 | |
| 11/5/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 180,000 | $67.00 | $12,060,000.00 | |
| 11/4/2014 | Fionnuala M Walsh | SVP | Sell | 15,000 | $67.00 | $1,005,000.00 | |
| 11/3/2014 | Enrique A Conterno | VP | Sell | 5,000 | $66.03 | $330,150.00 | |
| 10/31/2014 | Fionnuala M Walsh | SVP | Sell | 7,376 | $66.58 | $491,094.08 | |
| 10/31/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $66.40 | $12,616,000.00 | |
| 10/30/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 175,000 | $66.58 | $11,651,500.00 | |
| 10/24/2014 | Maria A Crowe | Insider | Sell | 2,750 | $65.77 | $180,867.50 | |
| 10/6/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $65.63 | $13,782,300.00 | |
| 10/1/2014 | Enrique A Conterno | VP | Sell | 5,000 | $64.86 | $324,300.00 | |
| 9/30/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $65.07 | $13,014,000.00 | |
| 9/10/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 210,000 | $64.77 | $13,601,700.00 | |
| 9/3/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $63.99 | $12,798,000.00 | |
| 9/2/2014 | Enrique A Conterno | VP | Sell | 5,000 | $63.60 | $318,000.00 | |
| 7/29/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 250,000 | $63.03 | $15,757,500.00 | |
| 7/28/2014 | Susan Mahony | SVP | Sell | 2,065 | $63.30 | $130,714.50 | |
| 7/25/2014 | Enrique A Conterno | VP | Sell | 10,000 | $63.79 | $637,900.00 | |
| 7/25/2014 | Susan Mahony | SVP | Sell | 30,000 | $63.90 | $1,917,000.00 | |
| 7/1/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 235,000 | $62.30 | $14,640,500.00 | |
| 6/25/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 245,000 | $62.68 | $15,356,600.00 | |
| 6/20/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 230,000 | $61.55 | $14,156,500.00 | |
| 6/16/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 200,000 | $58.73 | $11,746,000.00 | |
| 6/5/2014 | Lilly Endowment Inc | Major Shareholder | Sell | 190,000 | $59.53 | $11,310,700.00 | |
| 5/21/2014 | Lilly Endowment Inc | major shareholder | Sell | 230,000 | $58.90 | $13,547,000.00 | |
| 5/12/2014 | Jackson Tai | Director | Buy | 17,157 | $59.19 | $1,015,522.83 | |
| 5/12/2014 | Lilly Endowment Inc | major shareholder | Sell | 210,000 | $59.33 | $12,459,300.00 | |
| 5/6/2014 | Lilly Endowment Inc | major shareholder | Sell | 190,000 | $58.79 | $11,170,100.00 | |
| 4/29/2014 | Lilly Endowment Inc | major shareholder | Sell | 200,000 | $59.43 | $11,886,000.00 | |
| 4/28/2014 | Lilly Endowment Inc | major shareholder | Sell | 150,000 | $58.64 | $8,796,000.00 | |
| 8/15/2013 | Enrique Conterno | VP | Sell | 5,000 | $53.79 | $268,950.00 | |
| 7/29/2013 | Jacques Tapiero | SVP | Sell | 7,500 | $53.74 | $403,050.00 | |
| 7/15/2013 | Enrique A Conterno | VP | Sell | 5,000 | $51.43 | $257,150.00 | |
| 6/17/2013 | Enrique A Conterno | VP | Sell | 5,000 | $52.45 | $262,250.00 | |
| 5/15/2013 | Enrique A Conterno | VP | Sell | 5,000 | $56.15 | $280,750.00 | |
| 5/10/2013 | Jeffrey N Simmons | SVP | Sell | 10,000 | $54.49 | $544,900.00 | |
| 3/26/2013 | Susan Mahony | SVP | Sell | 5,000 | $56.00 | $280,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
| Source: |
|
| Date | Headline |
|---|
 | Axovant Sciences (AXON) Stock Crashed Over 70%: Here's Why
finance.yahoo.com - September 26 at 5:48 PM |
| J&J's Arthritis Candidate Sirukumab Denied FDA Approval
finance.yahoo.com - September 26 at 9:33 AM |
 | Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for ... - PR Newswire (press release)
www.prnewswire.com - September 25 at 7:04 PM |
| Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death
finance.yahoo.com - September 25 at 8:33 AM |
| Colorectal Cancer Market: Global Industry Analysis Trends, Share, Growth Drivers, Outlook and 2025 Forecasts Research Report
finance.yahoo.com - September 22 at 11:51 AM |
| Drug Makers Stocks on Investors' Radar -- Alliqua BioMedical, Immune Pharma, Eli Lilly, and Merck
www.prnewswire.com - September 22 at 11:51 AM |
 | Global Animal Health Market: Industry Analysis & Outlook 2017-2021 - Research and Markets
www.businesswire.com - September 21 at 3:49 PM |
| Recombinant DNA Technology Market Analysis By Product, By Component, By Application, By End-use And Segment Forecasts, 2014 - 2025
www.prnewswire.com - September 21 at 3:49 PM |
 | Eli Lilly and Company (LLY) Major Shareholder Sells $15,680,700.00 in Stock
www.americanbankingnews.com - September 18 at 4:16 PM |
| FY2017 EPS Estimates for Eli Lilly and Company Raised by Analyst (LLY)
www.americanbankingnews.com - September 18 at 2:56 AM |
 | Lilly/Incyte pill beats placebo in mid-stage eczema trial - Reuters - Reuters
www.reuters.com - September 17 at 12:44 AM |
| Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
finance.yahoo.com - September 16 at 6:04 AM |
| Eli Lilly Still Looking for Lower Prices
finance.yahoo.com - September 16 at 6:04 AM |
| Eli Lilly and Company (LLY) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - September 15 at 5:32 PM |
 | Eli Lilly & Co. (LLY) & Incyte Corp. (INCY) Announces Baricitinib Meets Primary Endpoint in Phase 2 Study
www.streetinsider.com - September 15 at 6:06 AM |
| Eli Lilly Partnering Deals and Alliances 2010 to 2017
finance.yahoo.com - September 15 at 6:06 AM |
| Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2017 (record date) : By the numbers : September 14, 2017
finance.yahoo.com - September 15 at 6:06 AM |
| Eli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.50 Billion
www.americanbankingnews.com - September 15 at 5:20 AM |
| Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
finance.yahoo.com - September 14 at 7:16 AM |
| Eli Lilly & Co. – Value Analysis (NYSE:LLY) : September 12, 2017
finance.yahoo.com - September 14 at 7:16 AM |
| Is Lilly Headed for the Valley?
finance.yahoo.com - September 14 at 7:16 AM |
| Zacks: Analysts Anticipate Eli Lilly and Company (LLY) to Announce $1.03 EPS
www.americanbankingnews.com - September 14 at 12:24 AM |
 | Lilly Cuts Back Again - Seeking Alpha
seekingalpha.com - September 13 at 5:53 AM |
| Eli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study
www.streetinsider.com - September 12 at 3:41 AM |
| Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
finance.yahoo.com - September 12 at 3:41 AM |
| Eli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : September 11, 2017
finance.yahoo.com - September 12 at 3:41 AM |
| Eli Lilly & Co. (LLY) Presents Clinical Evidence for CYRAMZA (ramucirumab) with Phase 3 RANGE Data ... - StreetInsider.com
www.streetinsider.com - September 11 at 10:38 PM |
| Eli Lilly & Co. (LLY) to Present New Data for Olumiant and Taltz at EADV - StreetInsider.com
www.streetinsider.com - September 11 at 10:38 PM |
| Eli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study - StreetInsider.com
www.streetinsider.com - September 11 at 10:38 PM |
| Eli Lilly and Company (LLY) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - September 11 at 5:46 PM |
| Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - September 10 at 6:00 AM |
| Lilly Breast Cancer Drug Results May Challenge Pfizer Pill
finance.yahoo.com - September 10 at 12:57 AM |
 | Eli Lilly to Cut 8% of Jobs, Invest More on New Drugs
www.wsj.com - September 9 at 7:55 PM |
| IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine
finance.yahoo.com - September 9 at 7:55 PM |
| Eli Lilly and Company (LLY) Earns "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 11:58 AM |
 | Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study
www.rttnews.com - September 9 at 5:18 AM |
 | Eli Lilly To Cut 8 Percent Of Jobs
www.msn.com - September 9 at 5:18 AM |
 | Eli Lilly Hopes to Benefit From Joining the Layoff Brigade — 3,500 Pink Slips!
247wallst.com - September 9 at 5:18 AM |
 | Drugmaker Eli Lilly Will Cut 3,500 Jobs
www.bloomberg.com - September 9 at 5:18 AM |
| Hurricane Irma Bears Down on Equities and Disney Slide Hits Dow
finance.yahoo.com - September 9 at 5:17 AM |
| IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
finance.yahoo.com - September 9 at 5:17 AM |
| Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective
finance.yahoo.com - September 9 at 5:17 AM |
| Understanding Merck’s Valuation after 2Q17
finance.yahoo.com - September 9 at 5:17 AM |
| Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018
finance.yahoo.com - September 9 at 5:17 AM |
 | Drugmaker Lilly to trim workforce by nearly 9 percent
abcnews.go.com - September 8 at 6:23 AM |
| SunTrust Banks Equities Analysts Raise Earnings Estimates for Eli Lilly and Company (LLY)
www.americanbankingnews.com - September 8 at 6:00 AM |
| Lilly to cut 8 percent of jobs in bid to cut costs - Reuters
www.reuters.com - September 8 at 1:33 AM |
 | Eli Lilly: 3,500 job cuts to make firm stronger, CEO says - USA Today - USA TODAY
www.usatoday.com - September 8 at 1:33 AM |
| PRESS DIGEST - Wall Street Journal - Sept 8
finance.yahoo.com - September 8 at 1:33 AM |
| [$$] Eli Lilly to Cut 8% of Jobs, Invest More on New Drugs
finance.yahoo.com - September 8 at 1:33 AM |
Eli Lilly and Company (LLY) Chart for Tuesday, September, 26, 2017
